Literature DB >> 8939883

Novel form of p21(WAF1/CIP1/SDI1) protein in phorbol ester-induced G2/M arrest.

W W Tchou1, W N Rom, K M Tchou-Wong.   

Abstract

Cell cycle progression requires activation of different cyclin-dependent kinases (CDKs) which are positively regulated by cyclins and negatively regulated by CDK inhibitors. Growth inhibition of the Calu-1 lung carcinoma cells induced with the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), a potent activator of protein kinase C, is associated with G2/M arrest and induction of expression of a novel, faster-migrating form of p21(WAF1/CIP1/SDI1) (p21) protein, an inhibitor of cyclin-dependent kinases. This faster-migrating p21 protein was also expressed in TPA-treated A549 lung carcinoma cells which also exhibited G2/M arrest but not in TPA-treated U937 leukemia cells, which only expressed a slower-migrating form of p21 protein. However, reverse transcriptase-polymerase chain reaction and Southern analysis demonstrated no evidence of novel splice in TPA-treated Calu-1 cells. On the other hand, immunoblotting analysis demonstrated that the faster-migrating p21 protein could be detected only by peptide antibody directed against the N terminus but not the C terminus, suggestive of truncation of the latter or protein modification that results in the loss of the C-terminal epitope. Correlation of G2/M arrest with expression of the faster-migrating p21 protein suggests that this novel form of p21 protein may be a mediator of G2/M arrest and growth inhibition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8939883     DOI: 10.1074/jbc.271.47.29556

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization.

Authors:  M Akashi; Y Osawa; H P Koeffler; M Hachiya
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

2.  p21(WAF1) is associated with CDK2 and CDK4 protein during HL-60 cell differentiation by TPA treatment.

Authors:  J W Cho; Y W Jeong; K S Kim; J Y Oh; J C Park; J C Lee; W K Baek; S I Suh; M H Suh
Journal:  Cell Prolif       Date:  2001-10       Impact factor: 6.831

3.  p53-independent expression of p21(CIP1/WAF1) in plasmacytic cells during G(2) cell cycle arrest induced by Actinobacillus actinomycetemcomitans cytolethal distending toxin.

Authors:  Tsuyoshi Sato; Takeyoshi Koseki; Kenji Yamato; Keitarou Saiki; Kiyoshi Konishi; Masanosuke Yoshikawa; Isao Ishikawa; Tatsuji Nishihara
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

4.  Establishment of a dog model for the p53 family pathway and identification of a novel isoform of p21 cyclin-dependent kinase inhibitor.

Authors:  Jin Zhang; Xiangling Chen; Michael S Kent; Carlos O Rodriguez; Xinbin Chen
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

5.  Sensitization of lung cancer cells to cisplatin by β-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of β-elemene and its synthetic analogs.

Authors:  Q Quentin Li; Gangduo Wang; Furong Huang; Jueli M Li; Christopher F Cuff; Eddie Reed
Journal:  Med Oncol       Date:  2013-02-09       Impact factor: 3.064

6.  Knockdown of nucleophosmin induces S-phase arrest in HepG2 cells.

Authors:  Qing-Qing Wang; Zhi-Yi Zhang; Jian-Yong Xiao; Chun Yi; Lin-Zi Li; Yan Huang; Jing-Ping Yun
Journal:  Chin J Cancer       Date:  2011-11-18

7.  p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells.

Authors:  Y H Choi; W H Lee; K Y Park; L Zhang
Journal:  Jpn J Cancer Res       Date:  2000-02

8.  Targeting cellular metabolism to reduce head and neck cancer growth.

Authors:  Jian Yang; Yuqi Guo; Wonkyu Seo; Ruohan Zhang; Cuijie Lu; Yaoyu Wang; Liang Luo; Bidisha Paul; Wenbo Yan; Deepak Saxena; Xin Li
Journal:  Sci Rep       Date:  2019-03-21       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.